Janssen Sciences Ireland Unlimited Company

Janssen R&d Ireland

Speedx Pty Ltd

Janssen Sciences Ireland Uc

Tibotec Pharmaceuticals Ltd.

Johnson & Johnson Research Pty Limited

Guenter Kraus

Lieven Elvire Colette Baert

Iksoo Chun

Qiang Zhang

Deborah M Schachter

Lieven Elvire Baert

Alison Velyian Todd

Elisa Mokany

Marie-Pierre T M M G De Bethune

Laurence Tatiana Rimsky

Bart Anna Julien Maes

Inky Paul Madeleine De Baere

Gerben Albert Eleutherius Van ′t Klooster

Gerben Albert Eleutherius Van 't Klooster

Marie-Pierre Tmmg De Bethune

Bart Anna Maes

Inky Paul De Baere

Gerben Albert Van 't Klooster

Pedro Miguel Lory

Marleen Clynhens

Tania Pauline Ivens

Edwin Yunhao Gong

Gerben Albert Eleutherius Van 'T Klooster

Marie-Pierre TMMG De Bethune

Tania Pauline Eduard Ivens

Pedro Miguel Jales Lory

This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered intermittently at a time interval of at least one week.

Long term treatment of HIV-infection with TMC278

A degradable, removable, pharmaceutical implant for the sustained release of one or more drugs in a subject, wherein the pharmaceutical implant is composed of a tube comprising an outer wall made of a degradable polymer completely surrounding a cavity, wherein the outer wall has a plurality of openings and wherein the cavity contains one or more sets of micro-particles, which micro-particles contain an active agent or a combination of two or more active agents, and wherein the size of the microparticles is selected such that the majority of the microparticles cannot pass through the openings.

Degradable removable implant for the sustained release of an active compound

The present invention relates to methods and means for the evaluation of HIV replicative capacity in a given environment. In particular, the invention provides a growth competition assay that can determine relative viral fitness using a recombinant tagged HIV-1 virus system. The methods rely on plasmid vectors, amplicons, primers and probes, and the generation of replication-competent viruses therefrom. Said methods and materials may find use in multiple fields including diagnostics, drug screening, pharmacogenetics and drug development.

Methods, plasmid vectors and primers for assessing HIV viral fitness

Growing community of inventors

Sint-Katelijne-Waver, Belgium

Guenter Kraus